Ironwood Pharmaceuticals, Inc. (IRWD)
IRWDNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$4.68
-0.0300 (-0.64%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $4.66 -0.43%
- Market cap
- $771.45m
- P/E
- 5.2
- EPS, last 4 quarters
- $0.9000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.88 to $5.78
- Average volume
- 1.96m
- Previous close
- $4.71
Analysts
1 coveringHold1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +28.2% from here
Earnings
next estimate $0.2500Next report
Dec 2025
-150.0%
Mar 2026
+242.9%
Jun 2026
+19.2%
Sep 2026
+20.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $47.71m | $106.51m | $113.04m | $133.04m |
| Gross profit | $47.71m | $106.51m | $113.04m | $133.04m |
| Operating income | $6.80m | $72.57m | $79.31m | $93.13m |
| Net income | -$2.28m | $40.77m | $51.29m | $59.84m |
Last four quarters: revenue $400.30m, margin 37.4%, free cash flow –
News
8 latest- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpZacks · 4 days ago
- Ironwood (IRWD) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Ironwood Pharmaceuticals Raises Full-Year 2026 Financial GuidanceFintel · 5 days ago
- Ironwood Q3 Net Income Rises 49%; Raises FY26 Revenue And EBITDA Outlook; Stock Up RTTNews · 5 days ago
- Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings EstimatesZacks · 5 days ago
- Ironwood Pharmaceuticals Promotes COO Tammi Gaskins To Succeed Tom McCourt As CEO RTTNews · Oct 16, 2026
- Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?Zacks · Oct 7, 2026
The company
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS (linaclotide), the U.S . branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts , with a site in Basel, Switzerland .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- ironwoodpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.